Connect your AI

Novavax NVAX Change in Other Assets

Change in Other Assets at other companies

ModernaMRNA

-$54M-17.4%

Roivant SciencesROIV

$1.85M-15.3%

Vaxcyte, Inc.PCVX

$8.74M+483%

Viridian Therapeutics, Inc.VRDN

$2.33M+919%

ALN

Alnylam PharmaceuticalsALNY

$6.32M-80.7%

Nektar TherapeuticsNKTR

-$949K-116%

Other financials

Income statement

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Novavax's change in other assets?: Novavax (NVAX) reported change in other assets of -$86.24M in Q1 2026.
How has Novavax's change in other assets changed year-over-year?: Novavax's change in other assets decreased by 16.8% year-over-year, from -$73.87M to -$86.24M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.